Genesense Technologies Inc.
8Patents
0Active
8Granted
24Portfolio score
Filing activity: Jun 30, 1997 → Oct 18, 2000
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6121000A | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase | Chemistry; Metallurgy | 34 | Expired |
| US6566514B1 | Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth | Chemistry; Metallurgy | 13 | Expired |
| US6417169B1 | Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth | Chemistry; Metallurgy | 5 | Expired |
| US6593305B1 | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase | Chemistry; Metallurgy | 3 | Expired |
| US6610539B1 | Antisense oligonucleotide sequences as inhibitors of microorganisms | Chemistry; Metallurgy | 2 | Expired |
| US7223849B1 | Oligonucleotides from the untranslated regions of housekeeping genes and methods of using same to modulate cell growth | Chemistry; Metallurgy | 0 | Expired |
| US6472376B2 | Suppression of malignancy utilizing ribonucleotide reductase R1 | Emerging Cross-Sectional Technologies | 0 | Expired |
| US7087580B2 | Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth | Chemistry; Metallurgy | 0 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.